Introduction
There is a large body of observational data that links vitamin D 3 active metabolite 1,25-dihydroxy vitamin D 3 to the function of the cardiovascular system. 1, 2 This nonclassical effect of vitamin D 3 is additional to the more classical role of vitamin D 3 on the mineral-calcium metabolism in bone. 3, 4 Clinical studies suggest (somewhat inconsistently) that elevated vitamin D 3 levels can lower arterial blood pressure. 5 However, there is a strong correlation between insufficient serum levels of vitamin D 3 that are observed in heart failure, myocardial infarction and elevation of arterial blood pressure. 6 In cross-sectional studies (National Studies carried out on vitamin D 3 receptor (VDR) knockout and 1-α hydroxylase-deficient mouse models showed elevated arterial blood pressure. 8, 9 Other studies carried out on spontaneous hypertensive rats have indicated that vitamin D 3 administration suppresses endothelium-dependent contraction of aorta in these models. 10, 11 Vitamin D 3 has antihypertrophic, anti-inflammatory and antiproliferative properties and may reduce cardiac hypertrophy in spontaneous hypertensive rats. 12 Furthermore, vitamin D 3 has a direct effect on endothelial and smooth muscle cells and may decrease coagulation and increase re-endothelialization and fibrinolysis. 12 The dysfunction of endothelium in the cardiovascular system is a common denominator of several diseases such as hypertension, diabetes, obesity and heart failure -all of which are diseases where an insufficient level of vitamin D 3 is observed. [13] [14] [15] The dysfunction of the endothelium is characterized by low production of bioavailable nitric oxide 16 (NO) -a cytoprotective vasorelaxant -and a high concentration of cytotoxic vasoconstrictor, peroxynitrite (ONOO − ). 17 ONOO − is one of the most powerful oxidants in the biological milieu, and at high concentrations ONOO − can considerably shift the redox balance in endothelium and negatively affect vascular function and hemostasis. 18, 19 Endothelial peroxynitrite is produced in the rapid diffusioncontrolled reaction of superoxide (O 2 − ) with NO. 20 There are two major sources of O 2 − in dysfunctional endothelium: NADPH oxidase and uncoupled endothelial nitric oxide synthase (eNOS). Partially uncoupled eNOS can concomitantly produce NO and O 2 − , in close proximity, potentially resulting in high levels of ONOO − . Therefore, uncoupled eNOS can be a very effective generator of ONOO − , which can trigger a cascade of redox events leading to endothelial dysfunction.
The study presented here uses nanomedical methods of measurement and analysis to elucidate the role of 1,25-dihydroxy vitamin D 3 (abbreviated as vitamin D 3 throughout the text) in the stimulation of NO and ONOO − . Normal and angiotensin II (Ang II)-induced dysfunctional human umbilical vein endothelial cells (HUVECs) of African Americans (AAs) and Caucasian Americans (CAs) were used in this study. Nanosensors were used for the in situ monitoring of the concentrations of NO and ONOO − after the treatment of dysfunctional endothelial cells with vitamin D 3 . We developed a unique nanosystem that can be used for the simultaneous direct measurement in situ of bioavailable NO and ONOO − in single endothelial cells. 21, 22 
endothelial cell culture
HUVECs of AA (pooled, n=6, age 26±3 years) and CA (pooled, n=7, age 27±2 years) donors were purchased from Lonza (Walkersville, MD, USA). Cells were grown in T-75 flasks (Greiner bio-one, Cat # 658175) and incubated in MCDB-131 complete medium (VEC technologies) at 37°C under 5% CO 2 and 95% air and passaged every 3-4 days. After reaching confluence, the monolayer cells were trypsinized and fully detached. MCDB-131 (10 mL) complete medium was then added to trypsinized cell suspension in order to inactivate trypsin. Cells were then centrifuged at 1,500 rpm for 5 minutes. The cell pellet was then resuspended in 3 mL of fresh MCDB-131 complete media. To maintain the cell culture passage, 1 mL of the cell suspension was transferred to each of the three T-75 flasks followed by addition of 11 mL of fresh MCDB-131 complete media. For measurement, cells were resuspended in MCDB-131 
Preparation of electrochemical nanosensors

NO and ONOO
− nanosensors (diameter 200-300 nm) were prepared according to the published procedure. 21, 22 Briefly, a carbon fiber (6 µm in diameter) was inserted into a glass capillary (80-100 µm in diameter). The tip (8-15 µm) of the capillary holding protruded carbon fiber was sealed with mixture of bee wax and rosin, and shortened/reduced to the diameter of 200-300 nm by heating in propane microburners. The active tip of the carbon fiber was then coated by electrochemical polymerization of monomeric TMHPPNi to form a conductive polymeric film. The polymeric TMHPPNi film was then coated with Nafion (1% in ethanol). Similarly, the ONOO − nanosensor was prepared by deposition of a conductive TNMPPMn polymeric film on the tip of the carbon fiber by cyclic voltammetry. The surface of the polymeric TNMPPMn sensor was then coated with poly(4-vinylpyridine). The sensors were stored at room temperature in a phosphate buffer (pH 7.4). The NO and ONOO − nanosensors have a detection limit of 1 and 3 nmol/L, respectively, and can be used separately or in tandem for the simultaneous measurements of NO and ONOO − concentrations. Each of the nanosensors sample a volume of about 3-10 picoliters.
The sensor's selectivity is based on the potential of NO or ONOO − oxidation/reduction, very rapid electron transfer (high current) generated in this reaction, as well as the preventative barriers for negatively charged species (NO 2 − , NO 3 − , dopamine, etc.) for the NO sensor and a barrier for positively charged species for the ONOO − sensor. Additionally, the response selectivity for NO was confirmed in separate experiments in the presence of inhibitor(s) of eNOS (N(G)-nitro-L-arginine methyl ester [L-NAME]) or scavengers of ONOO − (Mn(III) tetrakis) (4-benzoic acid) porphyrin chloride. The detection limit of sensors is 1×10 −9 mol/L for NO and 3×10 −9 mol/L for ONOO − . The response time (limited by sensor response and analytical data collection system) is better than 5 µs and was estimated based on the response time of the sensor and processing/storage time of analytical (electrical current) signal.
amperometric measurement of NO and ONOO − Three-electrode system consisting of a platinum wire (counter electrode), Ag/AgCl (reference electrode) and a tandem of NO and ONOO − nanosensors (working electrodes) was used. Amperometric curves of current (proportional to concentration) versus time were measured using a GAMRY dual potentiostat, at a potential of 0.56 V (versus Ag/AgCl) for NO and −0.32 V (versus Ag/AgCl) for ONOO − . HUVECs cultured in a well were incubated under 5% CO 2 and 95% O 2 and allowed to grow for 1-2 days. Nanosensors were positioned at a well-defined and reproducible distance from the membrane of a single endothelial cell. X, Y and Z positions of the nanosensors were monitored according to the following procedure: first, the sensor was placed about 50 µm above endothelial cells, with the help of a stereotactic remote-controlled micromanipulator (Sexsapex, Finland) and gradually lowered closer to the membrane of the "sacrificial" single endothelial cell. When the sensor touched the membrane, a small signal (piezoelectric current) and a mechanically stimulated NO signal were recorded. The position of the sensor was assumed as zero distance from the cell membrane (axis Z=0). From Z=0, the sensor was raised about 5 µm and transferred along the X and Y axes (keeping the Z axis constant) and positioned above another endothelial cell, separated about 50-70 µm from the "sacrificial" cell. The "sacrificial" cell could not be used for further measurements because it was mechanically distorted by the sensor. The positioning of the nanosensor at the well-defined distance (5±2 µm) from the cell membrane is necessary to obtain reproducible results. NO concentration decreases with the increase of distance away from the membrane surface. A distance higher than 100 µm, NO can no longer be detected by the nanosensor. 
− concentration was calculated by the standard addition method and/or by a standard calibration curve for each sensor before and after measurement. The nitric oxide nanosensor was calibrated by using a standard solution (range of about 20-600 nmol/L) prepared from stock solution of NO (saturated solution of NO 1.8 mM) in phosphate buffer (pH 7.4). A linear calibration curve was constructed from these measurements for each sensor. Also, a standard addition method was used to monitor the response of the sensor to subsequently added standard solution of NO. The concentration of NO standard was confirmed with UV-visible spectrophotometry (hemoglobin method) and/ or coulometry.
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The peroxynitrite nanosensor was also calibrated in amperometric mode by both, the calibration curve and the standard addition method. The absorbance of ONOO − was measured in standard solution using a UV-visible spectroscopy at a wavelength of 303 nm. 
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Vitamin D 3 improves endothelial function after about 7 s for CAs. For AAs, the peak of 328±21 nmol/L was reached after about 6 s. NO release was accompanied by relatively low production of ONOO − , with maximal concentrations of 150±12 nmol/L for CAs and 190±17 nmol/L for AAs. A relationship between the maximal NO concentration and the concentration of vitamin D 3 is shown in Figure 1C . Figure 5A and B Figure 5C and D) .
effect of modulators of eNOs and NaDPh pathway in ang II cellular model of hypertension
We used the ratio of [NO]/[ONOO − ] to elucidate the function of eNOS and NADPH in the Ang II cellular model of hypertension ( Figure 5C and D). L-NAME, a nonselective After 4 hours of incubation of HUVECs with Ang II, the eNOS expression was significantly upregulated in CAs and slightly in AAs ( Figure 6A ). Ang II further upregulated eNOS in HUVECs of both ethnic groups, and this effect was very significant after 12 hours of incubation. In contrast, vitamin D 3 treatment downregulated eNOS expression in HUVECs of both ethnic groups. This effect was highly significant after 12 hours of incubation with vitamin D 3 .
iNOS expression can be upregulated due to oxidative and nitroxidative stresses and/or inflammation. Therefore, we estimated iNOS expression in both Ang II-and vitamin D 3 -treated HUVECs. Ang II significantly upregulated expression of iNOS in HUVECs of both ethnic groups versus control groups after 4 and 12 hours of incubation ( Figure 6B ). Treatment with vitamin D 3 downregulated the expression of iNOS in HUVECs of both ethnic groups.
Ang II had minimal effect on the NADPH oxidase 4 expression after 4 hours of incubation; however, NADPH oxidase expression was upregulated after 12 hours ( Figure 6C ), indicating the effect of Ang II on the expression of enzymes 
Discussion
The nanomedical system utilized in these studies offers a unique opportunity to monitor in situ, the near real-time molecular changes of two signaling molecules, NO and ONOO − , produced by endothelial cells. The production of ONOO − increases with the increased rate of NO release. Therefore, any rapid stimulation of NO could be considered unfavorable for endothelial function due to the potential uncoupling of eNOS and enhanced ONOO − generation. Therefore, a modest rate of vitamin D 3 -stimulated NO release is of crucial importance to the proper function of endothelium and the cardiovascular system. This is one of the important findings of this study. Here, we used Ang II to produce dysfunctional endothelium, similar to that observed in hypertension. Treatment with vitamin D 3 , in this cellular model of hypertension, significantly restored bioavailable NO with the concomitant decrease in nitroxidative stress that is associated with high ONOO − . The moderate NO production by vitamin D 3 does not cause eNOS uncoupling. − by this enzyme. The dominating product of coupled eNOS dimer is NO, while in the uncoupled dimer of eNOS, a rapid direct oneelectron transfer to oxygen produces O 2 − . NO is the most effective scavenger of O 2 − , which produces ONOO − in a diffusion-controlled reaction. 23, 24 Therefore, vitamin D 3 treatment actively reduced endothelial production of O 2 − from two major sources: NADPH oxidase and uncoupled eNOS. The efficiency of O 2 − production by uncoupled eNOS in dysfunctional endothelium can be comparable to that generated by NADPH. Vitamin D 3 simultaneously decreases the level of O 2 − generated by these two sources, by reducing the level of NADPH on one side and then by limiting the generation of O 2 − from coupled eNOS dimer on the other side. This effect accounts for the reduction of oxidative/ nitroxidative stress and the overall increase in bioavailable NO -both a highly beneficial effect of vitamin D 3 treatment on endothelium and the cardiovascular system. The process of restoring bioavailable NO production by vitamin D 3 is more efficient and comprehensive than other possible pathways of the restoration of dysfunctional endothelium, like elevated levels of L-arginine, sepiapterin treatment, scavenging or dismutase of O 2 − . As shown here, L-arginine, sepiapterin or NADPH inhibition can only partially restore (20%-30%) endothelial function under physiologically acceptable concentrations.
In − and ONOO − ; coupled/uncoupled eNOS, iNOS and NADPH oxidase. All of these molecules and their sources may contribute to shift in oxidative/nitroxidative stress and bioavailability of NO. Upregulated expression of these three enzymes may lead to excessive oxidative stress in cellular environment, which effectively diminished the level of bioavailable NO. Furthermore, upregulation in the expression of iNOS, which is usually associated with inflammation, can contribute to this unfavorable effect. By design, iNOS is a secondary source of NO synthesis when there is a shortage of the NO generated by eNOS. High NO production by iNOS depletes L-arginine levels and accelerates the further uncoupling of eNOS and makes the recovery of eNOS dimer even more difficult. Additionally, the NO produced from iNOS contributes minimally to the overall level of bioavailable NO, but has a significant effect on the overall increase of ONOO − due to the scavenging of O 2
−
. This further exposes the cellular environment to severe oxidative and nitroxidative stress and endothelial dysfunction. Also, excessive O 2 − and ONOO − can oxidize tetrahydrobiopterin, BH 4 , an important cofactor of eNOS and a stabilizer of eNOS dimer. 27, 28 In the absence of BH 4 , eNOS produces mostly O 2 − . Supplementation of L-arginine and/or sepiapterin (precursor of BH 4 ) improved endothelial function by diminishing O 2 − and ONOO − concentrations. Our study provides direct molecular insight to previously published observations that have suggested that vitamin D 3 deficiency-induced hypertension is associated with vascular oxidative stress. 29 It is well documented that oxidative stress is involved in vascular complications and development of hypertension. 30 Oxidative and nitroxidative stress impairs endothelium-dependent relaxation of the blood vessels and is involved in the facilitation of smooth muscles contractions. [31] [32] [33] It has been suggested that oxidative stress is the main source of endothelial damage, and that it is generated by NADPH oxidase -one of the key enzymes of facilitating oxidative stress. We found here that the contributions of NADPH to the total oxidative stress is dominant in the initial stage of endothelial dysfunction. However, in severely dysfunctional endothelium, the contribution of NADPH to the total O 2 − was less than that generated from uncoupled eNOS (40% and 60%, respectively). Results of the studies presented here are coherent with and complementary to the results of previous observations. Scavengers and inhibitors of oxidative and nitroxidative stress partially prevent the dysfunction of endothelium. 34 It has been suggested that protective effect of AT1R blockers, the major class of antihypertensive drugs in patients with hypertension, is associated with their antioxidative action. 35, 36 In SHR, it has been found that vitamin D 3 reduces the expression of NADPH oxidase in the vasculature. 37 Vitamin D 3 treatment of renal arteries of hypertensive patients showed improved endothelial function and reduction in oxidative stress. 37 It was suggested that the downregulation of NADPH oxidase and the upregulation of SOD1 and SOD2 may be responsible for this effect. 37 Our studies support and confirm this hypothesis.
Based on clinical studies, it has been suggested that vitamin D 3 may improve NO, modulate vascular tone and lower blood pressure in patients with hypertension. 29 However, none of these studies provided any direct proof of how vitamin D 3 improves NO production and decreases nitroxidative stress. Our studies are not only coherent with previous observations, but provide new direct evidence, on the molecular level, why vitamin D 3 can be highly beneficial for the treatment of a dysfunctional cardiovascular system. We proved here by direct NO measurements that vitamin D 3 stimulated NO release within the first second of its exposure to endothelial cells. This rapid response of endothelium to vitamin D 3 suggests that this process is most likely controlled by VDRs that are present on endothelial cell membrane, 38 and is followed by the signal transduction through the calciumcalmodulin pathway. We suggest that the beneficial action of vitamin D 3 on the cardiovascular system can be explained solely based on the enhanced effect on endothelial NO levels and its depreciative effect on ONOO − levels. While the beneficial effects of vitamin D 3 on dysfunctional eNOS and endothelium is well supported by this research, the effect of a high level of vitamin D 3 on normal cells will require more studies to establish the potential for an unfavorable shift of [ 3 does not significantly scavenge for superoxide or peroxynitrite but attenuates oxidative/ nitroxidative stress and increases NO bioavailability by transcriptional regulation of the enzymes responsible for generating them. The net result is a decrease of the expression of iNOS and eNOS in the cellular environment. At low eNOS and iNOS expression, the available concentrations of major substrate, L-arginine and cofactor (BH 4 ) become more available for eNOS coupling.
Therefore, these studies are the first to identify the molecular mechanism of vitamin D 3 -triggered restoration of the function of eNOS and the function of endothelial cells in the cardiovascular system. While these studies were performed using a cellular model of hypertension, the implications of the influence of vitamin D 3 on dysfunctional endothelium is much broader. The dysfunction of endothelium is a common denominator of several cardiovascular diseases, particularly those associated with ischemic events. Therefore, we suggest that vitamin D 3 treatment may be of clinical importance in the restoration of dysfunctional cardiac endothelium after heart ischemia, capillary endothelium after brain ischemia, hypovolemia, vasculopathy, diabetes and atherosclerosis. Our suggestion is strongly supported by several clinical studies indicating that vitamin D 3 , at doses significantly higher than those currently used for the treatment of bone diseases, can be highly beneficial for the treatment of the dysfunctional cardiovascular system.
